# Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions

> **NCT07090525** · PHASE2 · RECRUITING · sponsor: **Qingdao Central Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Overall Response Rate

## Interventions

- **DRUG:** Intracavity injection of bevacizumab 7.5mg/kg plus cisplatin 40mg/m2
- **DRUG:** cisplatin 40mg/m2 intracavity injection

## Key facts

- **NCT ID:** NCT07090525
- **Lead sponsor:** Qingdao Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07090525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07090525, "Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07090525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*